TNXP stock forecast, quote, news & analysis
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases... Show more
Why Tonix Pharmaceuticals Holding Corp. (TNXP) Is Up +4% in the Last 30 Days
Key Takeaways
- TNXP stock rose approximately +4% over the last 30 days, driven by positive presentations on TONMYA for fibromyalgia and conference announcements boosting investor sentiment.
- Over the past quarter, the stock declined -7%, reflecting broader biotech sector pressures and post-earnings consolidation amid ongoing commercialization efforts.
- Recent Q4 and full-year 2025 earnings showed revenue growth to $13.1M from product sales including TONMYA launch, with cash position strengthened to $207.6M.
- Multiple data presentations and publications on lead product TONMYA enhanced market confidence in its fibromyalgia treatment potential.
- Preclinical immuno-oncology updates and upcoming conferences signal pipeline progress in CNS, immunology, and infectious diseases.
Tonix Pharmaceuticals Holding Corp. (TNXP) Company Overview and Market Position
Tonix Pharmaceuticals Holding Corp. (TNXP) is a fully integrated biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders, immunology, immuno-oncology, infectious diseases, and rare diseases. Its core business model centers on advancing novel small molecules and biologics through clinical development to address unmet medical needs, such as fibromyalgia pain and migraine, while building a diversified pipeline including vaccines and monoclonal antibodies.
Operating in the competitive biotechnology industry, Tonix holds a niche position with its recently launched TONMYA (cyclobenzaprine HCl sublingual tablet) for fibromyalgia—the first new chemical entity approved for this indication in over 15 years. Additional marketed products like Zembrace SymTouch and Tosymra for acute migraine provide revenue stability. The company's fundamentals, including Phase 3 successes and growing product sales, underpin recent stock resilience despite sector volatility, as commercialization ramps up and pipeline catalysts emerge.
Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, TNXP stock advanced from a close of $15.30 on February 19, 2026, to $15.94 on March 19, 2026, marking a +4.2% gain. The movement was volatile yet trend-driven upward, with shares fluctuating between $13.97 and $16.14 amid news flow, trading above the 50-day moving average of $15.55.
For the past quarter, the stock eased from $17.09 on December 19, 2025, to $15.94, a -6.7% decline. Performance was range-bound with downside pressure, reflecting biotech market trends and digestion of full-year results, while remaining well off the 52-week high of $69.97 but above the low of $13.07. Volume averaged around 400,000 shares daily, indicating steady interest.
What Drove TNXP Stock Price in the Last 30 Days
The modest uptick in TNXP's stock price stemmed primarily from heightened visibility around its lead fibromyalgia therapy, TONMYA. Key catalysts included presentations of Phase 3 post-hoc analyses at the 8th International Congress on Controversies in Fibromyalgia and data at the 2026 AAPM PainConnect Annual Meeting, underscoring efficacy in pain relief and sleep quality. A publication of pharmacokinetic studies in the Journal of Clinical Pharmacology in Drug Development further validated the product's profile.
Announcements of CEO presentations at BIO-Europe Spring 2026 and oral/poster sessions on the immuno-oncology portfolio at the AACR Annual Meeting 2026 fueled optimism. These events directly correlated with intraday surges, such as an 11.7% jump following the BIO-Europe news. Positive investor forum participation and Q4 2025 earnings highlighting TONMYA launch metrics—1,500 prescribers and 4,200 prescriptions—shifted sentiment amid stable revenue growth.
What Drove TNXP Stock Performance Over the Last Quarter
The quarterly decline reflected broader macroeconomic headwinds in biotech, including elevated interest rates and investor caution toward pre-profit developers, compounded by post-earnings profit-taking. Full-year 2025 results showed net product revenue up to $13.1M from $10.1M, driven by TONMYA's November launch and migraine products, but a $124M net loss highlighted R&D investments.
Sustained narratives around TONMYA commercialization provided a floor, with early metrics signaling adoption. Sector influences like regulatory delays in peers and funding constraints pressured small-caps, evident in TNXP's beta of 1.86. Institutional behavior remained supportive via a $20M direct offering, bolstering cash to $207.6M, yet competitive positioning in crowded CNS space tempered gains. Cumulative impact favored range-bound trading near support levels.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from among hundreds that analyze thousands of tickers across various markets. These curated bots employ diverse strategies, including trend-following, mean reversion, momentum, and pattern recognition, optimized for different timeframes from intraday to long-term swings. Performance metrics such as win rate, average return, Sharpe ratio, and maximum drawdown are transparently displayed, helping traders identify bots aligned with their risk tolerance and goals. Whether focusing on high-frequency scalping or swing trades, the section highlights those with consistent outperformance amid market trends. Explore the page to discover bots potentially suited for stocks like TNXP and enhance your trading with data-backed automation.
TNXP Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor TONMYA sales traction, including prescription growth and payer reimbursements, as commercialization scales. Upcoming conferences like BIO-Europe Spring and AACR could yield pipeline updates on immuno-oncology assets and infectious disease vaccines such as TNX-801.
Quarterly earnings will reveal revenue progression from migraine products and TONMYA amid R&D spend on candidates like TNX-102 SL expansions and TNX-1500 for transplant rejection. Macro factors including biotech funding environment, interest rates, and FDA feedback on ongoing trials remain key. Risks encompass clinical setbacks or dilution, while catalysts include partnerships or positive data readouts in CNS and rare diseases.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
TNXP sees its Stochastic Oscillator ascending out of oversold territory
On June 15, 2026, the Stochastic Oscillator for TNXP moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 17, 2026. You may want to consider a long position or call options on TNXP as a result. In of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TNXP just turned positive on June 17, 2026. Looking at past instances where TNXP's MACD turned positive, the stock continued to rise in of 34 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TNXP advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
TNXP moved below its 50-day moving average on May 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TNXP crossed bearishly below the 50-day moving average on May 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNXP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TNXP broke above its upper Bollinger Band on May 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TNXP entered a downward trend on June 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.843) is normal, around the industry mean (20.056). P/E Ratio (0.054) is within average values for comparable stocks, (35.868). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). TNXP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (7.153) is also within normal values, averaging (361.304).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. TNXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in developing and manufacturing pharmaceuticals
Industry Biotechnology